scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
47 hedge funds and large institutions have $89.6M invested in scPharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 13 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 13
0.55% less ownership
Funds ownership: 62.57% → 62.02% (-0.55%)
8% less funds holding
Funds holding: 51 → 47 (-4)
30% less capital invested
Capital invested by funds: $127M → $89.6M (-$37.7M)
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$492K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$355K |
| 3 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
+$302K |
| 4 |
VF
Virtu Financial
New York
|
+$285K |
| 5 |
Bank of New York Mellon
New York
|
+$256K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$5.49M |
| 2 |
EP
Eversept Partners
New York
|
-$489K |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$407K |
| 4 |
Renaissance Technologies
New York
|
-$399K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$316K |
SCPH Hedge Fund Activity: Q4 2020 in Review
47 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q4 2020, worth a combined $89.6M — down 30% from $127M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of SCPH and 9 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 16 added.
The largest buyer was BlackRock, adding an estimated $492K. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $5.49M sold.
- 47 institutional investors held scPharmaceuticals (SCPH) as of Q4 2020, down from 51 in Q3 2020.
- Funds reported $89.6M of scPharmaceuticals stock for Q4 2020, down 30% quarter-over-quarter.
- 9 funds opened new scPharmaceuticals positions in Q4 2020 and 13 closed out, a net change of -4 holders.
- The largest scPharmaceuticals buyer in Q4 2020 was BlackRock, an estimated $492K added.
- The largest scPharmaceuticals seller in Q4 2020 was Driehaus Capital Management, an estimated $5.49M sold.
Based on aggregated 13F filings for Q4 2020.